Carbimazole, Thiamazole (Methimazole)

Study	Exclusion reasons	Rmk	Reference
Andersen 2013 (control unexposed, disease free), 2013	repeat population groups, duplicate reports (most recent study included)	EXCLUDED: Andersen 2019 published an update analysis of this study Andersen 2013 based on a longer period and including more participants.	Andersen J. Clin. Endocrinol. Metab. 2013; 98:4373-81 10.1210/jc.2013-2831
Andersen 2013 (control unexposed, sick), 2013	repeat population groups, duplicate reports (most recent study included)	EXCLUDED: Andersen 2019 published an update analysis of this study Andersen 2013 based on a longer period and including more participants.	Andersen J. Clin. Endocrinol. Metab. 2013; 98:4373-81 10.1210/jc.2013-2831
Andersen 2013 (control exposed to PTU), 2013	repeat population groups, duplicate reports (most recent study included)	EXCLUDED: Andersen 2019 published an update analysis of this study Andersen 2013 based on a longer period and including more participants.	Andersen J. Clin. Endocrinol. Metab. 2013; 98:4373-81 10.1210/jc.2013-2831
Andersen 2014 (control unexposed, disease free), 2014	repeat population groups, duplicate reports (most recent study included)	EXCLUDED: Andersen 2019 published an update analysis of this study Andersen 2014 based on a longer period and including more participants.	Andersen Thyroid 2014; 24:1533-40 10.1089/thy.2014.0150
Andersen 2014 (control unexposed, sick), 2014	repeat population groups, duplicate reports (most recent study included)	EXCLUDED: Andersen 2019 published an update analysis of this study Andersen 2014 based on a longer period and including more participants.	Andersen Thyroid 2014; 24:1533-40 10.1089/thy.2014.0150
Andersen 2014 (control exposed to PTU), 2014	repeat population groups, duplicate reports (most recent study included)	EXCLUDED: Andersen 2019 published an update analysis of this study Andersen 2014 based on a longer period and including more participants.	Andersen Thyroid 2014; 24:1533-40 10.1089/thy.2014.0150
Momotani, 1977	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: no distinction between MMI and PTU exposure.	Momotani Nihon Naibunpi Gakkai Zasshi 1977; 53:1148-58 10.1507/endocrine1927.53.10_1148